CTI BioPharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	Current	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Market Capitalization	1,199	763	240	237	92	43
Market Cap Growth	-	218.03%	0.98%	159.24%	115.34%	-63.06%
Enterprise Value	1,256	792	222	189	67	-10
PE Ratio	-16.23	-8.20	-2.45	-4.53	-2.29	-1.45
PS Ratio	15.82	14.14	-	-	27.39	1.62
PB Ratio	-	-43.39	63.66	5.93	3.87	0.73
P/FCF Ratio	-	-9.39	-2.82	-5.62	-3.29	-1.07
P/OCF Ratio	-	-9.39	-2.82	-5.63	-3.29	-1.07
EV/Sales Ratio	16.58	14.68	-	-	20.09	-0.40
EV/EBITDA Ratio	-	-10.16	-2.33	-3.71	-1.75	0.38
EV/EBIT Ratio	-	-9.92	-2.32	-3.67	-1.72	0.37
EV/FCF Ratio	-	-9.75	-2.61	-4.49	-2.42	0.26
Debt / Equity Ratio	-4.59	-6.21	12.58	0.11	0.39	0.24
Debt / EBITDA Ratio	-2.25	-1.40	-0.50	-0.09	-0.24	-0.51
Debt / FCF Ratio	-1.41	-1.34	-0.56	-0.11	-0.33	-0.35
Quick Ratio	1.20	1.17	0.98	3.08	1.82	3.50
Current Ratio	1.27	1.23	1.03	3.19	1.92	3.58
Asset Turnover	0.61	0.42	0	0	0.05	0.26
Interest Coverage	-3.54	-6.08	-39.54	-62.35	-38.94	-23.25
Return on Equity (ROE)	425.90%	550.20%	-298.90%	-122.10%	-109.10%	-43.90%
Return on Assets (ROA)	-55.80%	-72.20%	-133.20%	-73.40%	-64.80%	-29.60%
Return on Invested Capital (ROIC)	-44.80%	-83.00%	1187.00%	-1464.30%	-227.70%	-105.30%
Earnings Yield	-5.78%	-12.19%	-40.83%	-22.09%	-43.69%	-69.11%
FCF Yield	-6.87%	-10.65%	-35.40%	-17.78%	-30.37%	-93.69%
Buyback Yield / Dilution	-31.78%	-27.27%	-26.67%	-22.71%	-3.39%	-53.86%
Total Shareholder Return	-31.78%	-27.27%	-26.67%	-22.71%	-3.39%	-53.86%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).